Sanofi India Limited - Asset Resilience Ratio
Sanofi India Limited (SANOFI) has an Asset Resilience Ratio of 19.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SANOFI working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Sanofi India Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SANOFI total asset value.
Liquid Assets Composition Over Time
This chart breaks down Sanofi India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SANOFI strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs2.30 Billion | 18.35% |
| Short-term Investments | Rs148.00 Million | 1.18% |
| Total Liquid Assets | Rs2.45 Billion | 19.53% |
Asset Resilience Insights
- Good Liquidity Position: Sanofi India Limited maintains a healthy 19.53% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Sanofi India Limited Industry Peers by Asset Resilience Ratio
Compare Sanofi India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for Sanofi India Limited (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Sanofi India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.53% | Rs2.45 Billion ≈ $26.50 Million |
Rs12.55 Billion ≈ $135.70 Million |
+0.93pp |
| 2024-12-31 | 18.59% | Rs3.00 Billion ≈ $32.41 Million |
Rs16.12 Billion ≈ $174.31 Million |
-0.98pp |
| 2023-12-31 | 19.57% | Rs3.36 Billion ≈ $36.29 Million |
Rs17.15 Billion ≈ $185.45 Million |
-28.03pp |
| 2022-12-31 | 47.60% | Rs9.86 Billion ≈ $106.64 Million |
Rs20.72 Billion ≈ $224.05 Million |
+47.20pp |
| 2021-12-31 | 0.40% | Rs123.00 Million ≈ $1.33 Million |
Rs30.61 Billion ≈ $331.04 Million |
-0.56pp |
| 2020-12-31 | 0.96% | Rs281.00 Million ≈ $3.04 Million |
Rs29.18 Billion ≈ $315.62 Million |
-31.50pp |
| 2019-12-31 | 32.46% | Rs10.53 Billion ≈ $113.89 Million |
Rs32.44 Billion ≈ $350.87 Million |
+4.58pp |
| 2018-12-31 | 27.88% | Rs8.32 Billion ≈ $89.97 Million |
Rs29.84 Billion ≈ $322.70 Million |
+17.02pp |
| 2017-12-31 | 10.86% | Rs3.02 Billion ≈ $32.62 Million |
Rs27.77 Billion ≈ $300.32 Million |
-9.11pp |
| 2016-12-31 | 19.97% | Rs5.07 Billion ≈ $54.85 Million |
Rs25.40 Billion ≈ $274.69 Million |
+27.18pp |
| 2015-12-31 | -7.21% | Rs-1.73 Billion ≈ $-18.75 Million |
Rs24.05 Billion ≈ $260.05 Million |
-18.33pp |
| 2011-12-31 | 11.12% | Rs1.67 Billion ≈ $18.07 Million |
Rs15.03 Billion ≈ $162.50 Million |
-7.11pp |
| 2010-12-31 | 18.23% | Rs2.57 Billion ≈ $27.77 Million |
Rs14.08 Billion ≈ $152.31 Million |
-- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more